This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stocks in play: Eupraxia Pharmaceuticals Inc.

Baystreet.ca - Baystreet - Wed Apr 22, 8:49AM CDT

Announced that the Company will present 4 abstracts at Digestive Disease Week Annual meeting being held May 2-5 in Chicago. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading up $0.12 at $9.75.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).